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Intracellular Dynamics of HIV Infection
Janka Petravic,a Paula Ellenberg,b Ming-Liang Chan,a Geza Paukovics,b Redmond P. Smyth,b* Johnson Mak,b,c,d Miles P. Davenporta
Complex Systems in Biology Group, Centre for Vascular Research, University of New South Wales, Sydney, NSW, Australiaa; Centre of Virology, Burnet Institute, Melbourne,
VIC, Australiab; School of Medicine, Deakin University, Geelong, VIC, Australiac; CISRO Livestock Industries, Australian Animal Health Laboratory, Geelong, VIC, Australiad
Early studies of HIV infection dynamics suggested that virus-producing HIV-infected cells had an average half-life of approxi-
mately 1 day. However, whether this average behavior is reflective of the dynamics of individual infected cells is unclear. Here,
we use HIV-enhanced green fluorescent protein (EGFP) constructs and flow cytometry sorting to explore the dynamics of cell
infection, viral protein production, and cell death in vitro. By following the numbers of productively infected cells expressing
EGFP over time, we show that infected cell death slows down over time. Although infected cell death in vivo could be very differ-
ent, our results suggest that the constant decay of cell numbers observed in vivo during antiretroviral treatment could reflect a
balance of cell death and delayed viral protein production.We observe no correlation between viral protein production and
death rate of productively infected cells, showing that viral protein production is not likely to be the sole determinant of the
death of HIV-infected cells. Finally, we show that all observed features can be reproduced by a simple model in which infected
cells have broad distributions of productive life spans, times to start viral protein production, and viral protein production rates.
This broad spectrum of the level and timing of viral protein production provides new insights into the behavior and characteris-
tics of HIV-infected cells.
Untreated HIV infection usually involves an initial acute phase,followed by a long period of stable viral load and clinical
latency, ending in severe CD4 T cell depletion and AIDS. The
long period of clinical latency initially led to the idea that the
intracellular viral replication cycle may also be extremely slow.
However, the subsequent studies of viral kinetics under treatment
revealed a highly dynamic process of infection. Despite the appar-
ent stability of viral loads and CD4 T cell numbers during the
observed clinical latency, there was a rapid turnover of both free
virus (half-life [t1/2] of 45 min) (1) and productively infected
cells (0.7 per day, which translates to a half-life of1 day) (2–4).
The understanding of in vivo viral dynamics under therapy has
been very helpful in elucidating the effects of antiretroviral treat-
ment (ART), the rate of viral evolution, and the mechanisms of
immune control. However, since the model was based upon the
dynamics of total virus produced by all productively infected cells,
it estimated the average death rate of infected cells or the average
rate of viral production.
Although this averaged replication cycle of productively in-
fected cells has proved extremely useful in understanding the
overall dynamics of infection, it may be missing a number of im-
portant underlying features at the intracellular level, where the
infected cells show a great variation in behavior (5). For example,
it has been observed that the rate at which HIV-infected CD4 T
cells release new virions varies greatly across the cell population
(6–8). The differences in viral protein production rates, on the
other hand, could have an impact on infected cell death because of
viral cytopathic effect, so the cells that produce viral protein at a
higher rate would on average have shorter life spans (9, 10). In
addition, differences in the rates of viral protein synthesis may also
have implications for immune recognition and control of infec-
tion, since the level of viral protein and viral production may
impact on factors such as CD8T cell recognition of infected cells.
Finally, our concepts of “productively” and “latently” infected
cells suggest a strict dichotomy. However, a spectrum of levels of
viral production would have major implications for our under-
standing of HIV latency and attempts to purge the latent reservoir.
A number of studies have investigated the distribution of viral
protein production across the population of infected cells. Studies
of viral production have been performed on visna virus infection
(11) and HIV-infected Jurkat cells (12–15). These studies sug-
gested that the translation of viral proteins proceeds at a wide
range of rates and seems to increase exponentially over time in
individual cells (6, 11, 15). The start of protein production in
HIV-infected Jurkat cells was also highly variable and seemed to
negatively correlate with the level of produced viral protein, which
has been linked to the position of the integration site within the
nucleus (14). Details of the steps in HIV provirus transcription
and translation leading to virus production in the SupT1 cell line
during the first 24 h of infection have also been recently studied
(16). However, the impact of viral protein production on cell
death could not be seen in the immortalized cell lines, and it is not
clear whether these observed dynamics of virus production and
cell death are consistent with the dynamics found in primary cell
infection.
The aim of this study was to understand the intracellular dy-
namics of HIV infection. In particular, we were interested in the
time between virus entry and the start of viral protein production,
distribution of viral protein production rates and life spans of
productively infected cells, and a possible correlation between the
distributions of virus protein production rates and death rates
across the infected CD4 T cell population. To this end, we have
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studied the dynamics of a single-round in vitro HIV infection of
healthy peripheral blood lymphocytes (PBLs) from 8 donors with
an HIV-enhanced green fluorescent protein (EGFP) reporter vi-
rus. The virus had egfp inserted within the nef coding sequence
that is under the regulation of the HIV long terminal repeat (LTR)
promoter. EGFP in infected cells was produced at the rate of trans-
lation of the Nef protein, so the production rate of EGFP is a
measure for the production rate of viral proteins. After initializa-
tion of protein production, EGFP accumulated in the cell cyto-
plasm, with the fluorescence correlated to the amount of EGFP
present in a cell. We followed the productively infected cell num-
bers and fluorescence distribution over 4 days after infection. In
order to investigate the diversity in EGFP expression and its im-
pact on cell fate, we also used a fluorescence-activated cell sorter
(FACS) to sort the productively infected cells into two groups at 24
h postinfection according to their fluorescence level, EGFP-high
and EGFP-medium, and followed them in parallel. We used sta-
tistical analysis and mathematical modeling to interpret the exper-
imental results.
We found the results consistent with a picture in which in-
fected cells had a broad distribution of times from infection to
production of viral protein (what we call “silent phase”), with a
similarly broad distribution of life spans from the start of produc-
tion of viral protein. Protein production also varied across the
infected cell population but was on average lower for the cells that
started protein production later. However, life spans of produc-
tively infected cells were independent of viral protein production
rates.
This study provides insights into the intracellular dynamics of
HIV infection that underlie the observed in vivo dynamics of viral
load after treatment. The observation of a wide distribution of
time from initial infection to viral protein production has impor-
tant implications for our understanding of cellular latency. Simi-
larly, the decrease in viral protein production levels observed in
cells that commenced producing later suggests that cells reactivat-
ing after prolonged treatment may behave differently from cells
that commence viral production immediately after infection. Al-
though our study relies on relatively short-term tracking of in
vitro-infected cells, it suggests a reevaluation of our concepts of
productive and latent infection.
MATERIALS AND METHODS
Experimental methods. (i) Virus production. The pNLAD8-EGFP
HIV-1 R5-tropic infectious clones contain the EGFP open reading frame
inserted into the nef gene.
Virus was produced by transfection of 293T cells, which were obtained
from the American Type Culture Collection and maintained in Dulbec-
co’s modified Eagle’s medium (DMEM) (Invitrogen, California) supple-
mented with 10% (vol/vol) cosmic calf serum (CCS) (HyClone, Toronga,
New Zealand) and penicillin-streptomycin (Invitrogen, Carlsbad CA).
Transfections were carried out with polyethylenimine (Polysciences
Inc., Warrington, PA), and transfection efficiencies were measured using
a reverse transcriptase assay (17). Thirty-six hours posttransfection, virus-
containing medium was harvested, clarified by centrifugation at 1,462 g
for 30 min, and then passed through a 0.45-m-pore-size filter (Sartorius,
Goettingen, Germany) to remove cellular debris. Purified virus was con-
centrated by ultracentrifugation using an L-90 ultracentrifuge (SW-31Ti
rotor; Beckman Coulter, Fullerton, CA) at 100,000  g for 1 h at 4°C
through a 20% sucrose cushion and resuspended in phosphate-buffered
saline (PBS). The concentrated viral stocks were quantified using the Vi-
ronostika HIV-1 antigen (p24 CA) microElisa (bioMérieux, Boxtel, Neth-
erlands) according to the manufacturer’s instructions and frozen in sin-
gle-use aliquots at80°C.
(ii) Cell culture. Peripheral blood mononuclear cells (PBMCs) were
isolated from buffy coats of random (identity-blocked) blood donors
(supplied by the Red Cross Blood Bank Service, Melbourne, Australia)
through density gradient centrifugation over Ficoll-Paque Plus (Amer-
sham Biosciences, Piscataway, NJ) as previously described (18).These cells
were then used for isolation of peripheral blood lymphocytes (PBLs) by
incubating PBMCs in plastic tissue culture dishes to remove adherent
cells. The purity of PBLs was assessed by flow cytometry (FACSAria; Bec-
ton, Dickinson, San Jose, CA) and determined to be95% pure based on
forward-scatter and side-scatter characteristics. The PBLs were stimulated
in medium (2 106 cells/ml) supplemented with 10g/ml phytohemag-
glutinin (PHA; Murex Diagnostics, Dartford, Kent, United Kingdom) for
3 days and then were transferred into fresh RPMI 1640 with 10% fetal
bovine serum (FBS) (SAFC Biosciences, KS) and 50 g/ml gentamicin
(Pfizer, Bentley, WA, Australia) containing 10 units/ml interleukin-2
(Roche Applied Science, Mannheim, Germany) 24 h before infection. All
biological samples were handled according to the Burnet Institute and the
Alfred Hospital-approved ethics guidelines, in line with Australian Gov-
ernment regulation.
(iii) Virus infection. Eight donor samples (one sample each from do-
nors 13, 14, 15, 23, 81, and 85 and two samples, 98(1) and 98(2), from
donor 98) were infected with 1 g of p24 capsid protein (CA) equivalent
of HIV/106 cells. Stimulated PBLs were spinoculated with the virus at
30°C for 2 h at 1,200 g and then incubated further for 1 h at 37°C and 5%
CO2. Subsequently, the cells were washed twice with PBS to remove un-
bound virus and incubated with media at 37°C and 5% CO2 for 4 days.
Antiretrovirals (20 M raltegravir and 500 nM zidovudine [AZT] ob-
tained from AIDS Research and Reference Reagent Program, Division of
AIDS, National Institute of Allergy and Infectious Diseases, U.S. National
Institutes of Health) were added to the culture media either 24 h before
the infection (pretreatment control) or 18 h after the infection (posttreat-
ment) and maintained throughout the experiment. Twenty-four hours
postinfection, the number of viable cells was calculated, and cell concen-
tration was adjusted across the different samples.
(iv) PKH-26 labeling. We used PKH-26 labeling to check if infected
cells were dividing. Five hours before HIV-1 infection, replicates of 2 
106 PBLs were collected, washed twice with PBS, and stained by following
the manufacturer’s instructions. Briefly, cells were resuspended in a solu-
tion of 2 M PKH-26 (Sigma-Aldrich, St. Louis, MO) and mixed vigor-
ously for 5 min. Then, RPMI 1640 and 10% FBS medium was added to
stop the labeling reaction. The cells were subsequently washed twice with
medium and finally resuspended in 2 ml RPMI 1640, 10% FBS, 50 g/ml
gentamicin, and 10 units/ml interleukin-2.
(v) FACS analysis. Two samples (from donor 15 and donor 23) were
FACS analyzed at 12, 15, 18, and 24 h postinfection. After 24 h, 7 donor
samples [from donors 13, 14, 23, 81, 85, and 98(1) and 98(2)] were ana-
lyzed by FACS and then FACS sorted into EGFP-medium (3	 log F	 4)
and EGFP-high (log F 4). Unsorted and sorted samples were then FACS
analyzed on day 2, day 3, and day 4.
Flow cytometry data were collected on a FACSAria flow cytometer
(BD Biosciences, Franklin Lakes, NJ) and analyzed with Flow-Jo software
(Tree Star, Ashland, OR) and FACSDiva (BD Biosciences, Franklin Lakes,
NJ). Cell sorting of viable cells was performed by employing FACSAria.
The PBL population was initially gated based on size (forward light scat-
ter) and granularity (side angle light scatter) characteristics. On day 1
postinfection, viable cells were sorted according to the levels of EGFP
expression into high, medium, and negative. Subsequently, cell density
was adjusted to 1.5 105 cell/ml, and cells were maintained in culture for
a further 3 days. Samples were taken after 2, 3, and 4 days postinfection
from the standardized cell cultures, to assess EGFP expression, cell num-
ber, and viability. When collecting the samples, cells were washed and
resuspended in PBS-1% CCS, adding 5 g/ml propidium iodide (Sigma-
Aldrich, St. Louis, MO) to estimate the number of viable cells. Also, a
Petravic et al.
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known number of CountBright counting beads (Invitrogen, Carlsbad,
CA) was added to the sample before analysis in order to calculate absolute
cell numbers.
Data analysis. (i) Half-life of GFP cells. Death rate 
 of EGFP
CD4 T cells between two time points, t1 and t2, was calculated assuming
exponential decline in the cell numbers between these two time points,
N(t2)  N(t1)exp[
(t2  t1)], where N(t) is a measured number of
EGFP cells at time t. Death rate is then obtained from
 
lnNt1 ⁄ Nt2
t2  t1
(1)
which corresponds to the half-life t1/2 ln2/
.
(ii) Cell number balance in unsorted cell cultures. The number of
EGFP cells at the end of each 1-day period, which were not EGFP at the
start of this period, can be estimated by balancing the cell numbers.
None of the EGFP cells present on day 1 were EGFP on day 0.
Therefore, the number of new EGFP cells on day 1 is equal to N(1), i.e.,
the total number of EGFP cells on day 1.
The number of cells that were not EGFP on day 1 but were EGFP on
day 2 can be estimated as follows. If N(1) is the number of EGFP cells on
day 1, and the death rate between day 1 (t1) and day 2 (t2) is 
12, then
these cells will be reduced to N(1)exp(
12) on day 2. Thus, the excess
number of cells on day 2, coming from the cells that became EGFP in this
period, is:
N2  N2 N1exp12t2  t1 (2)
In principle, 
12 should be determined from the decline of cell numbers in
the sorted medium and high cultures, in which cells die and are not re-
placed. However, cell numbers were not measured immediately after sort-
ing. Because of an observed decrease in death rate with time, for estima-
tion purposes, we assume that the death rate is at least equal to 
23 (but
may be higher). Therefore, our estimate is that at leastN2 new cells were
EGFP on day 2.
We can similarly estimate the number of new cells that were not
EGFP on day 2 but were EGFP on day 3 (N3) with the formula
N3  N3N2exp12 N1exp12exp23 (3)
and the number of new cells that were not GFP on day 3 but were GFP
on day 4 (N4) with the formula
N4  N4N3exp12N2exp12exp23
N1exp12exp23exp34
(4)
As before, we assumed 
12 
23 for estimation purposes.
(iii) Fluorescence distributions and MFI analysis. Fluorescence dis-
tributions obtained from FACS were aligned for comparison purposes so
that the autofluorescence peaks were at 102 relative fluorescence units
(RFU). On day 1, fluorescence distributions from all donors had the min-
imum after the background peak between log F of 3.55 and log F of 3.65.
We therefore chose log F of 3.6 as the threshold for defining the cells as
EGFP positive. Death rates and mean fluorescence intensity (MFI) of
EGFP cells in donor samples were obtained from aligned individual
distributions using this threshold.
(iv) Estimating EGFP degradation and production rate. We assume
that EGFP is produced and degraded at constant rate,
dG ⁄ dt p GFPG (5)
where G is EGFP level at time t, and p and 
GFP are production and
degradation rates, respectively. This would result in an exponential rise
from detection threshold G0 to a plateau G* p/
GFP,
Gt G G G0expGFPt (6)
Our aim was to estimate EGFP production and degradation rates (p and

GFP, respectively) for use in the mathematical model of the experiment.
For fitting purposes, we needed to combine MFI of the cell samples
followed during the first 24 h (from donors 15 and 23) with the MFI of the
cell samples measured on days 1, 2, 3, and 4 (from donors 13, 14, 23, 81,
85, and 98 [1] and 98 [2]). We used the average MFI of the unsorted
samples at 12, 15, and 18 h and the averages of the direct measurements of
MFI in the sorted high cultures on days 2, 3, and 4.
Because the EGFP cells in the medium EGFP fluorescence range on
day 1 were only a small fraction of all EGFP cells, we assumed that the
EGFP cells that appeared during the first 18 h gave rise to mostly EGFP-
high cells. The averaged MFI in sorted EGFP-high cells on day 1 was found
from the fluorescence distributions of unsorted samples on day 1 and the
sorting threshold for EGFP-medium and EGFP-high. We then fitted
equation 6 to the combined early (12 to 18 h) data and EGFP-high data to
obtain the average EGFP degradation and average protein production in
cells sorted high. The estimate of the protein production in cells sorted
medium was obtained from the average EGFP level on days 2 to 4 and the
obtained EGFP degradation rate.
Modeling details. (i) Simulation parameters. In a simple model in
which infected cells start producing viral proteins at a constant rate after a
postinfection delay, and do so for the rest of their life span, some param-
eters could be estimated directly from the experiment, and the rest were
determined so as to reproduce experimental results.
The distribution of life spans from the start of protein production was
chosen as lognormal, with the mean and standard deviation chosen so that
they result in the average cell death rates for days 2 to 3 and days 3 to 4,
similar to those experimentally observed in medium- and high-sorted
cells. The probability density function for the natural logarithm of life
span lntl (where lifetime tl is in days) was given by normal probability
density (defined by the mean and the standard deviation in parentheses):
fn(lntl; ln0.5,1) (see Fig. 5B).
The number of new EGFP cells at the start of each day did not decay
exponentially in time, which we would expect if all cells had the same
probability of starting protein production after DNA integration. There-
fore, we chose the probability density for time from infection to starting
EGFP production (in days) to be lognormal, so that its natural logarithm
lntp is distributed normally: fn(lntp; ln1.2,0.8). The parameters for the start
of protein production were chosen so that they give numbers of new
EGFP cells as observed in the experiment, when combined with the
average death rates (Fig. 5C).
EGFP half-life was set as 9 h from the estimate obtained by fitting.
Production rate had a lognormal distribution with the mean p neg-
atively correlated with the time between start of production and integra-
tion tp. For the early producers, the mean early production rate p0 was
estimated from the exponential rise fit to the evolution of MFI in the
high-sorted cell population. Standard deviation of lnp0 was estimated as
0.8 from the width of the unsorted fluorescence distribution on day 1. The
probability density function for the logarithm of the early production rate
p0 was fn(lnp0; 11.5,0.8), where production is in RFU/cell/day.
In order for the MFI of the fluorescence distribution in the unsorted
samples to decrease after day 2, there has to be a negative overall correla-
tion between the time to start production and production rate. We chose
a steplike dependence of mean production rate and the start of production
(a slow decrease until day 1.5, and then a fast decrease till day 2, and finally
a slow decrease later) in order to reproduce the steplike decrease of MFI
between day 2 and day 3. The results were not very sensitive on the exact
choice of the function.
(ii) Simulation details. In a typical simulation, we would have 2 105
infected cells. At the start, each cell was assigned a time of virus entry (te)
from a uniform distribution from 0 to 2 h (mimicking 2 h of spinocula-
tion), fixed initial minimum delay (ti) (6 h), time to start of production
after the minimum delay (tp), and life span (tl) from the corresponding
lognormal distributions, as well as a protein production rate (p) chosen
from a positive normal distribution determined by its time to start pro-
duction.
At the cell-dependent time, t0 te ti tp, a cell would start produc-
ing protein at its rate p, and its EGFP content would be updated according
to equations 5 and 6 until its time of death, td  t0  tl. Fluorescence
Intracellular Dynamics of HIV Infection
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distributions and EGFP cell numbers (with log F of3.6) were collected
at 12, 15, and 18 h and on days 1, 2, 3, and 4.
RESULTS
In an attempt to synchronize the infection, we spinoculated the
stimulated peripheral blood lymphocytes (PBLs) from 7 donor
samples with the HIV-EGFP virus for 2 h (see Materials and Meth-
ods for details). After 18 h of infection, AZT and raltegravir were
added in order to prevent any second round of infection or de-
layed viral integration events, which could misalign the synchro-
nized infection among different HIV-infected cells.
In order to study the early rate of EGFP production over the
first day of infection, EGFP fluorescence was monitored every 3 to
6 h in two samples, starting at 12 h postinfection. As early as 12 h
postinfection, we noticed a low peak in EGFP fluorescence ap-
pearing above the large autofluorescent peak (at 102 RFU in the
cultures), representing the emergence of infected cells producing
EGFP. From 12 to 24 h, we observed a steady increase in both the
fraction and MFI of viable EGFP cells (we used viability dye to
exclude dead cells), corresponding to an increasing number of
cells commencing production of viral protein, as well as an in-
creased EGFP content of infected cells already in the production
stage (Fig. 1A).
At 24 h, the samples varied in the absolute percentage of viable
EGFP cells (reflecting the variability of permissiveness to infec-
tion across the donor population [5]) but had broad fluorescence
distributions of similar width and mean fluorescence intensity
(Fig. 1B). Following these infected cells over time, we observed
that both MFI and number of productively infected cells were still
somewhat increasing from day 1 to day 2, subsequently dropping
in both MFI and cell number over days 3 to 4 (Fig. 1C).
Having a broad distribution of EGFP fluorescence at any time
could have different origins. For example, in one picture, infected
cells may increase their EGFP content to intrinsically different
saturation levels, resulting in a distribution of fluorescence inten-
sities. Alternatively, they may be increasing their fluorescence at
different rates to an essentially similar final level or until death. By
separating the EGFP cells with lower EGFP expression on day 1
from those with high EGFP fluorescence and following them over
time, we could distinguish between these two possibilities.
The change of EGFP fluorescence distributions over time
could also be an outcome of different scenarios. If the distribution
of EGFP levels included cells that always have very low fluores-
cence, then the drop in mean fluorescence intensity on days 3 and
4 could be the result of the bright cells with high EGFP content
dying earlier, leaving a larger proportion of the dimmer cells viable
on later days. Another possibility is that all cells did not start viral
protein (and EGFP) production at the same time after integration
and that the cells that started producing later reached lower EGFP
levels. Separating the cells that were EGFP positive on day 1 and
then following their number and fluorescence would help us dis-
tinguish between these two processes.
In order to understand the variation in EGFP content, as well
as untangle the possible correlations of viral protein production
with infected cell death or start of viral protein and EGFP accu-
mulation, we FACS sorted the viable cells into EGFP-medium
(3	 log F	 4) and EGFP-high (log F4) populations, as indi-
FIG 1 Fluorescence distributions obtained in different phases of experiment. (A) The first EGFP cells appear 12 h postinfection, and their number and
fluorescence increase during the first 24 h. (B) Fluorescence distributions of all donor samples on day 1 have similar positions of peaks, although they differ in
the fraction of EGFP cells. On day 1, cells were FACS sorted into EGFP-medium (103	 F	 104; inside the white region in panel B) and EGFP-high (F 104;
inside the green region in panel B). (C) Averaged fluorescence distributions of unsorted samples on day 1, day 2, day 3, and day 4 show that EGFP cell numbers
and fluorescence first increase and later decrease (from day 2 onward). However, in the sorted EGFP-medium (D) and EGFP-high (E), cell numbers decline
monotonically while fluorescence is not changing much. The dashed vertical lines in panels A to C represent the EGFP gate. Error bars represent variations in
cell proportions (A) or numbers (C to E) across donor samples.
Petravic et al.
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cated in Fig. 1B. The proportion of infected cells was low (at most
3% of all viable CD4T cells), and although the sorting of cells on
day 1 removed most of the cells not expressing EGFP, it still left
part of the tail of the putatively uninfected peak. For consistency of
the data analysis of EGFP cell numbers and MFI, we narrowed
the definition of EGFP cells to the fluorescence interval 3.6	 log
F 	 4 (the dashed vertical line in Fig. 1 marks log F  3.6, the
EGFP threshold).
The changes in the averaged unsorted and sorted fluorescence
distributions over time are shown in Fig. 1C to E. The sorting of
cells into EGFP-medium and EGFP-high removed most of the
background signal due to the putatively uninfected cells that did
not express EGFP. Therefore, the sorted populations represent the
cells that have started EGFP (and HIV protein) production before
day 1, uncomplicated by the possible later appearance of new
EGFP cells. By comparing the fluorescence and cell numbers in
the unsorted and sorted productively infected cell populations
over time, we could deduce how the start of viral protein produc-
tion and cell death correlated with protein accumulation level and
production rate.
Distribution of EGFP fluorescence. The mean fluorescence
intensity (MFI) of EGFP in unsorted and sorted cell cultures over
4 days, averaged over all donor samples, is shown in Fig. 2. We saw
the first EGFP cells above background as early as 12 h postinfec-
tion (Fig. 1A and 2A). MFI then increased monotonically in the
first 24 h (Fig. 2, open circles). At 24 h, we saw a broad distribution
of EGFP levels across cells in each sample (Fig. 1). Upon sorting of
EGFP cells into those with lower (“medium”) and higher
(“high”) fluorescence, the MFI of medium-sorted EGFP cells
(squares in Fig. 2A) was at sorting (on day 1) approximately 3
times lower than the MFI of the cells sorted as high (triangles in
Fig. 2).
However, 24 h later and over the next 2 days (days 2 to 4), both
sorted cell populations had MFIs within the high range (104
RFU), suggesting that the early EGFP-medium state may have
been transient. Although the cell numbers in the sorted cell cul-
tures declined steadily over this period, their MFI appeared stable.
Indeed, EGFP level in the sorted cultures did not change signifi-
cantly over this period (high, Fig. 2B, P  0.4861, Friedman test
with Dunn’s multiple comparison posttest; medium, Fig. 2C, P
0.4861, Friedman test with Dunn’s multiple comparison posttest,
suggesting that the EGFP fluorescence had reached a plateau by
day 2.
This is consistent with a picture of infected cells initially pass-
ing through a low/medium EGFP fluorescence stage and reaching
a final fluorescence level that has an inherent broad distribution in
the high range over the infected cell population. Interestingly,
although EGFP-medium cells increased their MFI rapidly into the
“high” range, they still had on average approximately 30% lower
EGFP content than EGFP-high cells over the period from days 2
to 4.
In contrast, in the unsorted samples (black circles in Fig. 2A),
after the initial increase, the average EGFP MFI decreased between
day 2 and day 3 (P	 0.0145, Friedman test with Dunn’s multiple
comparison posttest; Fig. 2D).
As mentioned before, this could be either because the cells with
a higher fluorescence died faster or because the cells becoming
EGFP later had a lower final EGFP level. We shall investigate
each scenario separately. However, in order to distinguish be-
tween these two possibilities, we first need to estimate the death
rates of productively infected cells and the rates at which cells
become EGFP on successive days.
Cell death and EGFP fluorescence. To understand the inter-
play of EGFP content, viral protein production, and death of pro-
FIG 2 Change of the average mean fluorescence intensity over time. During the first 24 h of infection, MFI increases monotonically (open circles in panel A). On
day 1, cells were sorted into EGFP-medium (solid squares) and EGFP-high (solid triangles) and were followed in parallel with the unsorted cells (solid circles).
(B and C) From day 2, neither MFI of EGFP-high nor of EGFP-medium changed significantly. (D) In the unsorted samples, MFI dropped significantly between
day 2 and day 3.
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ductively infected cells, we monitored the number of EGFP-in-
fected cells in sorted and unsorted cultures over time. However, in
measuring cell death, we also needed to take into account the
possibility of cell division. As a control experiment, we included in
our analysis the cell dye PKH-26, in order to measure cell division
by dye dilution. Consistent with previous studies (19), we found
that EGFP-producing cells do not divide in culture (data not
shown), which is most likely due to Vpr-induced cell cycle arrest,
so we ignored division of infected cells as a factor in total infected
cell number.
Figure 3A shows the average decay of the number of EGFP
cells over a 3-day period, in the unsorted, EGFP-medium, and
EGFP-high samples. Samples were standardized/scaled by the
number of EGFP cells present on day 2. In the unsorted popula-
tions, EGFP cell numbers decayed more slowly than in the sorted
populations. This is an indication that the EGFP-negative cells,
which make up a large proportion of the unsorted cell cultures,
could contain a potential source of new EGFP-positive cells (in-
fected cells that are yet to start actively producing EGFP) that
appear later. Because of this, the observed decay of the number of
productively infected cells could reflect the balance of cell death
and possible later appearance of new productively infected cells
from the large EGFP-negative cell population. By FACS sorting
cells into EGFP-medium and EGFP-high on day 1, we removed
the majority of EGFP-negative cells, so the sorted cell cultures
reflected the infected cell death dynamics more directly. We used
the decay of EGFP cell numbers in the sorted cell cultures to
estimate the death rate of productively infected cells.
Slowing down of death rate in time. If the probability of the
cells dying were the same in all cells and constant over time, then
the decay would be a single exponential and a straight line on a
logarithmic scale. However, Fig. 3A indicates that the death rates
of productively infected cells could slow down over time.
As a first estimate, we compared the average decay rates of the
number of EGFP cells between days 2 and 3 postinfection to the
average decay rates between days 3 and 4 postinfection (Fig. 3A).
In the first period (days 2 to 3), the decay rates are 0.973 day1 in
the sorted medium and 1.004 day1 in the sorted high cultures
(corresponding to half-lives of 0.71 days and 0.69 days, respec-
tively), while in the second period (days 3 to 4), the decay rates are
0.445 day1 in the sorted medium and 0.564 day1 in the sorted
high cultures (half-lives of 1.56 days and 1.23 days, respectively).
This represents an average 50% reduction of death rate from the
period between day 2 and 3 to the period between day 3 and 4.
The decay rates of EGFP cells in individual samples for the
“medium” and “high” cells are shown in Fig. 3B. In both types of
sorted cultures, the slowing down of the cell loss from the first
1-day period to the next was statistically significant (medium, P
0.0313; high, P  0.0469; Wilcoxon paired test), with cell death
increasing in the later period only in one sample (from donor 81 in
sorted EGFP-high).
These results suggest that the death rate of productively in-
fected cells slows down in time since infection (or in other words,
that the half-life of surviving cells increases in time). Our under-
standing of the HIV life cycle is based largely on estimates of av-
erage turnover of productively infected cells, which would imply
that the life spans would be exponentially distributed, although
they could still in principle vary widely over cell population. The
apparent slowing down of turnover of productively infected cells
means that infected cells are a heterogeneous set in terms of their
FIG 3 Cell death in unsorted and sorted cell cultures. (A) Change in EGFP-positive cell numbers over time, scaled by the cell number on day 2. From day 2, cell
numbers decline in all samples. Decline in the unsorted cell populations is slower than in the sorted. (B) In sorted cell cultures, the decline rate slows down in time
significantly. (C) There is no difference in the rates of decay of cell numbers between EGFP-medium and EGFP-high cells in the same time period. (D) However,
in the unsorted cell populations, EGFP cells are lost at the same rate between days 2 and 3 and between days 3 and 4.
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intrinsic longevity, with a significant proportion of longer-lived
cells (larger than expected from an exponential distribution of life
spans). Such a distribution of life spans may be consistent with a
lognormal distribution or a similar distribution with a “fat tail”
(4, 20).
Death rate of productively infected cells is not correlated
with EGFP level. If the infected cells with higher expression of
EGFP died faster, then we would expect that (i) in the fluorescence
distributions for the sorted cell cultures (Fig. 1D and E), the cells
with higher EGFP fluorescence would disappear faster, so the dis-
tributions would progressively lose the high-fluorescence part, (ii)
consequently, MFI of both the unsorted and the sorted cell distri-
butions would decrease in time, and (iii) the death rate of produc-
tively infected cells in the EGFP-medium samples would be lower
than in the EGFP-high samples, because they have consistently
lower MFI (Fig. 2A).
However, there is no evidence of the decrease of MFI in the
sorted cell cultures. Instead, we have a consistent level or even a
slight increase in MFI over time (Fig. 2B and C). The death rate of
EGFP-medium cells is not significantly different from the death
rate of the EGFP-high cells (Fig. 3C; P 1.000 for medium com-
pared to high on days 2 to 3, and P  0.3125 on days 3 to 4;
Wilcoxon paired test). This suggests that the distribution of pro-
ductively infected cell life spans is the same for all cells once they
start productive infection and that it is not related to the level of
EGFP in a cell.
Time to becoming EGFP positive. The decay of the EGFP
cells in the unsorted samples from their peak at day 2 appeared
exponential and slower than the decay of the cells in the sorted
cultures (Fig. 3A). Indeed, the analysis showed that the difference
in death rate between the two consecutive time periods in the
unsorted population was not significant (Fig. 3D, P 0.375, Wil-
coxon matched pair test), while the EGFP cell decay in the un-
sorted samples was also significantly slower than in the sorted
samples (P 0.0027 for days 2 to 3 and P 0.0289 for days 3 to 4,
Friedman test with Dunn’s multiple comparison posttest). The
average decay rate was 0.532 day1, consistent with the half-life of
productively infected cells estimated from in vivo studies of viral
decay dynamics under therapy. Thus, the unsorted cell population
behaved as expected from the in vivo studies of viral dynamics
after treatment, with a constant decay rate of productively infected
cells. However, this is quite different from initially rapid and then
slowing death rate of sorted cells.
Since the main effect of sorting was to eliminate a large pro-
portion of cells that were not expressing EGFP, it seems likely that
the reason for this slower decline in EGFP cell numbers in un-
sorted cell cultures is that the death of productively infected cells is
being compensated by the emergence of new EGFP cells over
time. That is, although we added AZT and raltegravir to block
integration 18 h postinfection, there may be a number of cells in
the silent phase that have already integrated the HIV genome but
did not immediately proceed to productive infection. Indeed, it
seems highly likely that there might be a distribution in the times
from provirus integration to significant EGFP production and
positive expression of EGFP.
Using the EGFP cell numbers available for each day in the
unsorted cell population belonging to each donor, and death rates
found in the sorted cultures for each period, we can estimate how
many cells would be present the next day if the changes in cell
numbers were caused only by death. For all donors, there are more
EGFP cells present the next day in the unsorted population than
expected just from cell death. The excess cells present each subse-
quent day can be interpreted as new EGFP cells appearing during
this period. The estimated number of new EGFP cells at the end
of each 1-day period is shown in Fig. 4.
Since at the time of infection there were no EGFP cells, all
EGFP cells after 1 day were “new” EGFP cells. After 48 h, there
were almost equally as many new EGFP cells that were not pos-
itive a day before. The number of new EGFP cells diminished
after day 2, but new cells were still appearing on day 3 and day 4.
The number of new EGFP cells on consecutive days did not
decline exponentially, suggesting a lognormal (or other “fat-
tailed”) distribution of times from infection to start of EGFP ex-
pression above the threshold (log F 3.6).
Associationbetween start ofEGFPproductionandEGFPflu-
orescence. We have found that the drop in EGFP fluorescence in
the unsorted cell cultures between day 2 and day 3 could not be
explained by increased death of the cells that had accumulated
higher levels of EGFP. On the other hand, we have also found that
cells can start EGFP and viral protein production a long time after
provirus integration. The new EGFP cells that appear later than
24 h postinfection would contribute to the infected cell fluores-
cence distributions of the unsorted cultures on days 2 to 4 but not
to the cultures that were FACS sorted on day 1. Therefore, the
drop in MFI that appears only in the unsorted samples between
day 2 and day 3 suggests that the cells that start producing EGFP
later have reduced EGFP expression compared to that of the cells
that started to produce earlier.
Since we could not directly measure the start of EGFP produc-
tion and fluorescence of individual cells, we used mathematical
modeling to investigate the plausibility of this scenario and to
estimate the type of correlation between the time to start of EGFP
production and EGFP production rate.
EGFP fluorescence and EGFP production and degradation
rate. FACS analysis measures the EGFP fluorescence of cells,
which is directly proportional to the amount of EGFP protein in
the cell cytoplasm at any time. If EGFP synthesis proceeded at a
constant rate, and a fixed proportion of it were degraded per unit
of time, the EGFP content would rise from zero to a plateau. The
final plateau level of EGFP would then represent the balance be-
tween EGFP production and degradation and would be directly
proportional to the ratio of the rate of synthesis to the degradation
FIG 4 New EGFP cells in the unsorted samples appearing on each day. The
number of new EGFP cells appearing on consecutive days is scaled by the
number of new EGFP cells appearing on day 1.
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rate. The change in MFI in Fig. 2A supports this model: MFI in-
creases over the first 24 h, and the cells sorted as EGFP on day 1
(sorted cultures) have a stable MFI level from day 2 onward.
The time taken to reach the plateau can give us an indication of
the half-life of EGFP: fluorescence will reach the plateau faster for
higher degradation rate (or shorter EGFP half-life). If we assume
constant EGFP production and degradation rates, we can estimate
these two parameters by fitting the exponential rise of MFI in the
high-sorted cell population, as explained in Materials and Meth-
ods. This gives the estimate of the half-life of the Nef-EGFP fusion
protein as approximately 9 h, which is much faster than 26 h that
had been estimated as the half-life of free EGFP (21).
We estimated the mean EGFP production rates for the EGFP-
high- and EGFP-medium-sorted cells as 6.0 104 and 4.2 104
RFU/day, respectively, meaning that the mean EGFP production
rate in the medium-sorted culture was around 30% lower than in
the samples sorted as EGFP-high. However, the distributions of
EGFP fluorescence (and the associated EGFP production rates,
since the production rates are proportional to EGFP fluorescence
at the plateau) in these sorted cultures were broad and partly over-
lapped.
Assuming that the EGFP decay rate is relatively constant
among cells from the start of production, cell fluorescence at the
plateau is a measure of EGFP production rate (and thus the pro-
duction rate of Nef protein). Our results suggest that viral protein
production rates have a wide distribution among cells and that
this distribution shifts toward lower average EGFP production
rates for the cells becoming EGFP positive at later times.
The conceptual model we describe of the delay until EGFP
production in an infected cell and then the sudden switch from no
EGFP production to full production is likely an oversimplification
of a true process. The delay from infection to EGFP production
may in part occur because of the variation in the time to proviral
integration, if the completely reverse-transcribed DNA can persist
in activated cells for similarly long periods of time as in resting
cells (22), without being degraded by cellular defense mecha-
nisms. However, this delay cannot account for greater than an
18-hour delay, since raltegravir was added at this time. Following
this, viral protein production may be delayed due to either a poor
integration site or cellular factors inhibiting viral activation. Once
viral protein production is initiated, it may increase at rates that
could vary across cell population, until they reach, again variable,
maximum levels. However, the fastest accumulation of EGFP
would be after production had reached the plateau, and because of
the high EGFP degradation rate, cells would cross the EGFP de-
tection threshold when the production rate was constant. The
delay time in our model would then consist of the time without
any production and the time during which viral proteins were
being translated but have not yet accumulated to detectable levels.
Modeling the dynamics of HIV protein production and cell
fate during primary cell infection. Our analysis separated differ-
ent aspects of cellular and viral dynamics in order to explain the
observed features of the experimental data. However, our esti-
mates of different parameters of the HIV replication cycle were
made by analyzing different aspects of infection independently
and in isolation. A major question is whether the factors we con-
sidered, acting together as schematically represented in Fig. 5A,
would reproduce the behavior of the system.
In setting up the simulation, we used the parameters estimated
from experimental results. The distribution of EGFP production
rates was taken to be lognormal in order to reproduce the bell-
shaped appearance of the fluorescence distributions of sorted cells
on log scale (Fig. 1D and E), with standard deviations roughly
estimated from the width of the unsorted fluorescence distribu-
tions on day 1. Lognormal distributions were also used to repre-
sent the experimental fat-tailed distributions of EGFP cell life
spans (Fig. 5C) and the times from infection to the start of EGFP
production (Fig. 5B). The parameters for the lognormal distribu-
tion (the mean and the standard deviation of log-life span) of life
spans were chosen so that they reproduce the observed average
death rates between days 2 and 3 and between days 3 and 4. The
distribution of times to start of production was chosen so that it
approximately reproduced the average experimental values on
days 1, 2, 3, and 4. Different types of fat-tailed distributions
roughly following the same pattern at the experimental time
points would have given the same result. EGFP degradation rate
was taken as 2 day1, as estimated from the MFI of sorted cells.
However, the results were not strongly sensitive on this particular
choice of parameters. Thus, this simplified model could essentially
be described by three distributions, for the delay between infec-
tion and the start of production of viral proteins, the life span of
cells after starting protein production and protein production
rate, and one constant parameter for EGFP degradation rate.
Using these three distributions and one parameter, where the
means were chosen based upon experimental data, we modeled
the changes in fluorescence and EGFP cell numbers over the first
24 h, the distribution of fluorescence on the first day, and the
subsequent behavior of the cells sorted as EGFP-high and EGFP-
medium.
A stochastic simulation consisted of 2  105 infected cells in
total, followed over 4 days. At the start, each infected cell was
allocated parameters for the time to initiate EGFP production, the
life span of productive infection (time from initial protein pro-
duction to death), and the level of EGFP production, drawn from
the lognormal distributions of these parameters. In each EGFP-
producing cell, the fluorescence increased to a plateau, the in-
crease described by exponential rise from the interplay of EGFP
production and degradation (equation 6).
This simulation could reproduce the general shape of fluores-
cence distributions and the change in MFI in sorted cell cultures,
as well as the appearance of new EGFP cells and the survival
curves of EGFP cells in the sorted and unsorted samples. How-
ever, one aspect of cell behavior that could not be reproduced with
such a minimalist model in which all parameters were uncorre-
lated was the decline in MFI in the unsorted population. That is,
although the overall cell number in the unsorted population could
be faithfully reproduced, we did not see the observed decrease in
EGFP fluorescence between day 2 and day 3, but the MFI in the
unsorted distribution stayed constant during this period. Even
when we added the assumption that the cells that produce EGFP
and viral proteins faster have shorter life spans, we were not able to
reproduce the observed decline in MFI, but it drastically changed
the decline of cell numbers and the appearance of the sorted dis-
tributions.
In the next set of simulations, we required that the cells that
initiated protein production later also had on average a lower
mean EGFP production rate. In this case, the mean of the lognor-
mal distribution of production rates was a monotonically decreas-
ing function of the time to start production, with the same stan-
dard deviation (Fig. 5D). Thus, in this set of simulations, the
Petravic et al.
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distributions were again estimated from experimental results,
with only the correlation between the time of start and production
rate adjusted in order to obtain the observed decrease in MFI in
unsorted cells. For simplicity, we used a steplike decrease of pro-
duction rate with time (Fig. 5D). The shape of MFI time depen-
dence in sorted cells at later times is similar to the dependence of
protein production rate on the start of production, because in our
model of EGFP production and destruction, the final EGFP fluo-
rescence of a cell is proportional to EGFP production rate.
The fluorescence distributions of the simulated infected cell
population closely mimicked the observed unsorted and sorted
infected cell behavior over time in shape, infected cell number,
and fluorescence (Fig. 6A). Tracking of the cell numbers in the
sorted cell populations after simulating the sorting protocol at 24
h postinfection also revealed a two-phase decay seen in vitro, while
the unsorted population exhibited single-exponential decay (Fig. 6B),
with new EGFP cells appearing in numbers similar to experi-
mental numbers each day (Fig. 6C). Importantly, in the evolution
of MFI over time, we obtained the drop of the MFI between day 2
and day 3 as in the experimental unsorted population (Fig. 6D). In
the sorted cells, MFI of the cells sorted as medium increased into
the high range but always stayed below the MFI of the cells sorted
as EGFP-high. This effect in the sorted populations was not the
result of the correlation between the timing of EGFP production
and production rate (since the average production rate did not
begin to decrease till after day 1) but was just a consequence of
having a distribution of production rates, with the lower end of
the distribution becoming EGFP later than the higher end. Thus,
the observed infected cell dynamics can be explained by simple
distributions of parameters, provided that the average protein
production rate is negatively correlated in a steplike way to the
timing of production. We note that although we used lognormal
FIG 5 The model and parameters used in simulation. Schematic representation of the model is shown in panel A. Cells with integrated HIV that have not yet
started protein production are shown in pink. They start producing viral proteins at different, lognormally distributed times (B). Once cells have initiated viral
protein production, they produce protein at a constant rate, and their EGFP content increases in time to a saturation level (cells turning green in panel A). EGFP
saturation level is directly proportional to the rate of production of EGFP. The life spans for protein-producing cells are lognormally distributed (C) irrespective
of their protein production rates. The distribution of protein production rates is negatively correlated with the production starting time (D). For each starting
time, protein production rate has a lognormal distribution (green bell-shaped curves on log scale in panel D), but the peak of this distribution corresponds to a
lower production for later starting times. This means that the cells that start producing protein later have lower average EGFP saturation levels (cells turning
lighter green when starting producing later in panel A).
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distributions for the different parameters in the model, any “fat-
tailed” distribution (such as gamma distribution) would produce
a similar result.
DISCUSSION
Studies of in vivo HIV viral kinetics under therapy have provided
significant insights into the average replication cycle of HIV in
infected cells. The exponential decline of viral load observed in
vivo on ART would at first glance imply a constant death rate of
productively infected cells. However, it is possible that individual
infected cells have nonexponential distributions of life spans and
intracellular delays and still produce an overall dynamic of expo-
nential decay (23). The nonexponential variation in the duration
of the silent phase can lead to different estimates of the turnover of
infected cells and free virus clearance (24) and cause slowing down
of the decay of viral load in the late stages of drug treatment (25).
Ignoring the variation in both the infected cell life spans and the
intracellular delays can cause large underestimates of the basic
reproductive ratio of the virus and of the efficacy of the antiretro-
viral therapy necessary to control the infection (23). If a large
variation in viral protein production rates implies a similar varia-
tion in the rates of release of new virions, which then also on
average negatively correlates with the timing of the start of pro-
duction, this could further modify our estimates of the parameters
of HIV infection and our understanding of viral decay during
treatment.
Previous analyses of viral kinetics in vivo have presented a sim-
plified model of the behavior of the average productively infected
cell. In this in vitro study, we investigated the distribution of virus
protein production rates, infected cell life spans, and silent-phase
times across the infected CD4 T cell population. Our analysis
suggests that the simple average behavior may be at odds with
some underlying complexities. In particular, our analysis suggests
that cells differ in their susceptibilities to death, with an accumu-
lation of longer-lived cells over time. On the surface, this seems
inconsistent with the observed exponential decay of virus in vivo.
However, we also show that the faster-dying, early-producing cells
were replaced by infected cells with delayed viral protein produc-
tion profiles over the first few days of infection. This resulted in
exponential decay of productively infected cells in the almost syn-
chronously infected cell culture and may contribute to the ob-
served exponential decay of viral load in patients receiving drug
treatment.
Despite every effort to ensure synchronized infection by add-
ing raltegravir and AZT, cells appeared to switch on fluorescence
after a wide range of postintegration times, with around 15% of
cells that became EGFP 2 days or more postinfection. The rate of
EGFP production seemed slower in the cells that initiated produc-
tion later. This negative correlation is similar to the results ob-
served in synchronously infected Jurkat cells, where the probabil-
ity of starting translation of viral proteins has been associated with
the position of the viral integration site, activation status, and
availability of Tat protein. The activated infected CD4 T cells
with disadvantageous integration sites had lower probabilities of
transactivation and also lower EGFP expression (14).
Our study suggests that only approximately 45% of all cells that
FIG 6 Reproduction of the main experimental results by the model. (A) Fluorescence distributions have the same general appearance over time, with MFI of the
unsorted distribution decreasing after day 2, and the sorted distributions stable after day 2. The EGFP cell numbers decline faster in the sorted (medium and
high) cell populations than in the unsorted, with decline rate slowing down in time (C). The new EGFP cells appearing on each day (red line in panel D) closely
follow the estimates from the experiment (box plot in the background of panel D).
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became EGFP positive during 4 days had done so by 24 h postin-
fection. This has implications for studies wishing to separate vi-
rus-producing from transcriptionally silent infected cells (26), as
just because a cell was not producing EGFP at 24 h does not mean
it may not have done so later in the days immediately postinfec-
tion. Determining the mechanisms of the delay in viral protein
production also has important implications for understanding la-
tency in vivo. The delay may occur due to a disfavored integration
site of the virus or alternatively because of a cellular activation
state or a cofactor that inhibited viral activation. That there ap-
pears a wide distribution in times from infection to viral produc-
tion, and a decrease in protein production in cells that produce
virus later, suggests quite a different picture from the traditional
concept of a simple dichotomy of productive versus latent infec-
tion. Understanding this distribution and the mechanisms behind
it may have important implications for therapies aimed at activat-
ing and purging the latent reservoir (27).
Surprisingly, we found that the EGFP cell life span was not
correlated to EGFP fluorescence and therefore to EGFP produc-
tion in a cell. Since EGFP fluorescence and content was found to
directly correlate with the quantity of p24 in the supernatant of
Jurkat cells in a similar experiment (13), this might suggests that
cell death is uncorrelated with viral protein content and viral pro-
tein production rate. However, the life span of infected cells since
infection would be longer for the cells that have a longer silent
phase, i.e., the cells that also have lower EGFP production rates. It
has been shown recently that HIV integration can cause CD4 cell
death and that integrase inhibitors such as raltegravir can rescue
cells (28). The lack of correlation between viral protein produc-
tion level and the death of productively infected cells may suggest
that viral proteins may not be cytotoxic in the cells that have sur-
vived the integration events.
Our in vitro study did not incorporate immune mechanisms
such as CD8T cells specific for the virus. The in vivo death rate of
infected cells may be influenced by cell killing by host cytolytic
effector mechanisms that are not represented in the in vitromodel.
Recognition of infected cells would depend on the viral protein
expression and therefore on protein production rate, which could
lead to the negative correlation between viral protein production
rate and productive life span of infected cells in vivo. In addition,
the in vivo dynamics may be different following infection of other
cell types, including CD4 cells that are not recently activated.
However, the similarity between the death rate of infected cells we
observe in vitro and that estimated in vivo is consistent with argu-
ments that CD8 T cells may not affect the death rate of produc-
tively infected cells (29–31).
Our in vitro studies have a number of limitations. First, it was
necessary to stimulate PBLs in vitro to achieve sufficient infection
rates for sorting. This may have contributed to our observation of
the relatively uniform EGFP content of sorted cells analyzed later
in infection. This would seem initially to contradict the previous
observation from confocal microscopy imaging (6–8) that a pop-
ulation of high- and low-virus-producing cells may coexist. How-
ever, we note that we also observed that cells becoming EGFP
positive later in infection must have lower EGFP content. Thus, a
cross-sectional analysis of images (as performed in references 6
and 7) might show a mix of recently infected cells that have higher
virus production rates and cells infected some time ago. Identify-
ing whether there are phenotypic differences between cells pro-
ducing EGFP early and late in vitro may be helpful.
In this experiment, we measured the EGFP content in HIV-
infected cells as a proxy for viral protein production but have not
directly investigated production and release of new virions. Since
FACS identifies only EGFP content in a cell, it is in principle pos-
sible that some cells produced high levels of viral protein but failed
to efficiently assemble and release virus, whereas other cells re-
leased new virions more efficiently and therefore had lower pro-
tein content. In a single-cell experiment with HIV-EGFP-infected
Jurkat cells, EGFP fluorescence and viral protein production pos-
itively correlated with the virion release rate (13), but this might
not be true in healthy PBLs. In addition, since the new budding
virions use the host cell membrane proteins to generate an enve-
lope, it is possible that this process may increase the probability of
cell death, so that cell death rate may correlate with the rate of
release of new virions. One future challenge would be to directly
measure virus release by normal EGFP-HIV-infected CD4 T
cells in a single-cell experiment.
The study of viral dynamics has been crucial for our under-
standing of HIV infection and has been used to challenge the way
we treat infected individuals. In this study, we measured the dy-
namics of viral infection in vitro. We showed that this system
recapitulates the average behavior of the total infected cell popu-
lation, as expected from in vivo studies of viral dynamics. How-
ever, our study revealed that the behavior of the total infected cell
population masks the inherent heterogeneity of the infection,
which exhibits a broad range of different trajectories. The wide
distribution of times from infection to viral protein production
could combine with broad distributions in protein production
levels and infected cell life spans to reproduce the average dynam-
ics observed in vivo. Extrapolating from our results using short-
term in vitro culture, we may speculate that infected cells could
form a quasi-continuum of increasing silent phases and decreas-
ing viral protein production rates, with productively infected and
latently infected cells representing successive ranges within this
continuum. Future studies will be needed to investigate the mech-
anisms underlying these broad distributions and whether this
contributes to immune control in vivo.
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